J Korean Surg Soc.  2009 Oct;77(4):238-245. 10.4174/jkss.2009.77.4.238.

Prognostic Factors Influence on the Systemic Recurrence in Axillary Lymph Node Negative Breast Cancer

• Lee HS
• Kwak BS
• Son BH
• Ahn SH

• KMID: 1464880
• DOI: http://doi.org/10.4174/jkss.2009.77.4.238

Abstract

PURPOSE
Axillary lymph node metastasis is one of the most important prognostic factors in breast cancer. Previous reports show differences that clinicopathologic factors influence the systemic recurrence and survival in axillary lymph node negative breast cancer. Thus, we have attempted to determine the prognostic factors influence on the systemic recurrence and survival in axillary lymph node negative breast cancer. METHODS: We retrospectively reviewed the data of 1,351 node negative breast cancer patients who underwent curative surgery to determine the prognostic factors such as age, sex, body mass index (BMI), family history, bilateral breast cancer, operation method, tumor size, stage, histologic grade, number of resected lymph nodes, hormone receptor status, overexpression of p53 and c-erbB2, and adjuvant therapy that influence the systemic recurrence and 10-year-distant relapse-free survival. RESULTS: Systemic recurrence occurred in 58 patients (4.3%) during 53.3 months median follow up period. The tumor size (P=0.001), stage (P=0.005), histologic grade (P=0.049). ER (P=0.028), PR (P=0.002), overexpression of p53 (P=0.001) and bilateral breast cancer (P=0.043) were statistically significant factors that influenced the systemic recurrence. In multivariate analysis, only tumor size was associated with the systemic recurrence (P=0.003). Tumor size (P=0.004), histologic grade (P=0.035), ER (P=0.046), PR (P=0.001) and bilateral cancer (P=0.003) were statistically significant factors that influenced 10-year-distant relapse-free survival. CONCLUSION: The larger tumor size was determined to be an independent prognostic value in axillary lymph node negative breast cancer.

Keyword

Axillary lymph node negative breast cancer; Systemic recurrence; Prognostic factor

MeSH Terms

Body Mass Index
Breast
Breast Neoplasms
Follow-Up Studies
Humans
Lymph Nodes
Multivariate Analysis
Neoplasm Metastasis
Recurrence
Retrospective Studies

Figure

• 

  Fig. 1 10-year-distant relapse-free survival according to tumor size (A), histologic grade (B), estrogen receptor (C), progesterone receptor (D), p53 overexpression (E), and bilateral breast cancer (F).

Reference

1. Ministry for Heath, Welfare and Family Affairs. Annual Report of Cancer Incidence (2005) and Survival (1993~2005) in Korea. 2008. 20–23.

2. The Korean Breast Cancer Society. Nationwide Korean breast cancer of 2004 using breast canser registration program. J Breast Cancer. 2006. 9:151–161.

3. Son BH, Ahn SH, Kwak BS, Kim JK, Kim HJ, Hong SJ, et al. The recurrence rate, risk factors and recurrence patterns after surgery in 3700 patients with operable breast cancer. J Breast Cancer. 2006. 9:134–144.

4. Kuru B, Camlibel M, Gulcelik MA, Alagol H. Prognostic factors affecting survival and disease-free survival in lymph node-negative breast carcinomas. J Surg Oncol. 2003. 83:167–172.

5. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007. 18:1133–1144.

6. McGinnis LS, Menck HR, Eyre HJ, Bland KI, Scott-Conner CE, Morrow M, et al. National Cancer Data Base survey of breast cancer management for patients from low income zip codes. Cancer. 2000. 88:933–945.

7. Adair F, Berg J, Joubert L, Robbins GF. Long-term followup of breast cancer patients: the 30-year report. Cancer. 1974. 33:1145–1150.

8. Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Intern Med. 2002. 137:678–687.

9. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007. 57:43–66.

10. Min YK, Kim NR, Cho SJ, Kim A, Bae JW, Koo BH. The clinical significance and prognosis of Korean young age (younger or 35 year old) onset breast cancer. J Korean Breast Cancer Soc. 2001. 4:74–79.

11. Park SH, Kim SI, Park BW, Lee KS. Prognostic factors in axillary lymph node negative breast cancer. J Korean Breast Cancer Soc. 2004. 7:111–120.

12. Christian MC, McCabe MS, Korn EL, Abrams JS, Kaplan RS, Friedman MA. The National Cancer Institute audit of the National Surgical Adjuvant Breast and Bowel Project Protocol B-06. N Engl J Med. 1995. 333:1469–1474.

13. van der Hage JA, Putter H, Bonnema J, Bartelink H, Therasse P, van de Velde CJ. Impact of locoregional treatment on the early-stage breast cancer patients: a retrospective analysis. Eur J Cancer. 2003. 39:2192–2199.

14. Kute TE, Russell GB, Zbieranski N, Long R, Johnston S, Williams H, et al. Prognostic markers in node-negative breast cancer: a prospective study. Cytometry B Clin Cytom. 2004. 59:24–31.

15. Younes M, Laucirica R. Lack of prognostic significance of histological grade in node-negative invasive breast carcinoma. Clin Cancer Res. 1997. 3:601–604.

16. Baak JP, Colpaert CG, van Diest PJ, Janssen E, van Diermen B, Albernaz E, et al. Multivariate prognostic evaluation of the mitotic activity index and fibrotic focus in node-negative invasive breast cancers. Eur J Cancer. 2005. 41:2093–2101.

17. Amadori D, Silvestrini R. Prognostic and predictive value of thymidine labelling index in breast cancer. Breast Cancer Res Treat. 1998. 51:267–281.

18. Ma H, Bernstein L, Pike MC, Ursin G. Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res. 2006. 8:R43.

19. Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res. 2007. 9:R6.

20. van der Wal BC, Butzelaar RM, van der Meij S, Boermeester MA. Axillary lymph node ratio and total number of removed lymph nodes: predictors of survival in stage I and II breast cancer. Eur J Surg Oncol. 2002. 28:481–489.

21. Weir L, Speers C, D'Yachkova Y, Olivotto IA. Prognostic significance of the number of axillary lymph nodes removed in patients with node-negative breast cancer. J Clin Oncol. 2002. 20:1793–1799.

22. Barnes DM, Dublin EA, Fisher CJ, Levison DA, Millis RR. Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? Hum Pathol. 1993. 24:469–476.

23. Choi NK, Kim SY, Kim TY, Chae MK, Baek MJ, Lim CW, et al. clinical correlation of c-erbB-2, p53, bcl-2, and c-myc expression in patients with breast cancer. J Korean Surg Soc. 2002. 62:371–380.

24. Jobsen JJ, van der Palen J, Ong F, Meerwaldt JH. Synchronous, bilateral breast cancer: prognostic value and incidence. Breast. 2003. 12:83–88.

25. Kroenke CH, Chen WY, Rosner B, Holmes MD. Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol. 2005. 23:1370–1378.

26. Loi S, Milne RL, Friedlander ML, McCredie MR, Giles GG, Hopper JL, et al. Obesity and outcomes in premenopausal and postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev. 2005. 14:1686–1691.

27. Whittemore AS, Stearman B, Venne V, Halpern J, Felberg A, McGuire V, et al. No evidence of familial correlation in breast cancer metastasis. Breast Cancer Res Treat. Epub 2009 Mar 19.